Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital

Anouchka SeesaghurP. EggerJoshua WardenAli AbbasiBethany LevickMajid RiazPeter McMahonMatthew D. ThompsonSue Cheeseman2026-03-222026-03-22202310.1136/bmjopen-2022-069214https://doi.org/10.1136/bmjopen-2022-069214https://andeanlibrary.org/handle/123456789/44005Citaciones: 6In this study identifying BM diagnosis from both structured and unstructured data, a high proportion of patients did not receive a BTA. Unstructured data provide new insights on the real-world use of BTA.enMedicineProstate cancerBone metastasisBreast cancerHealth recordsLung cancerElectronic health recordOncologyMetastasisProstateAssessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospitalarticle